Heron Therapeutics: Four Horse Race Of Approved Therapies
…
2,147$
-3,72%
Echtzeit-Aktienkurs Heron Therapeutics
Bid:
Ask:
Nachrichten zur Heron Therapeutics Aktie
Heron Therapeutics: Approved Therapy With Blockbuster Potential But Meager Revenues
…
Heron Therapeutics, Inc. (HRTX) Q3 2024 Earnings Call Transcript
…
CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer
SOUTH SAN FRANCISCO, Calif, Oct. 02, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an…
Heron Therapeutics, Inc., (HRTX) Q2 2024 Earnings Call Transcript
…
Heron Therapeutics, Inc. 2024 Q2 - Results - Earnings Call Presentation
…
Heron Therapeutics: Opioid-Free Surgical Pain Relief Maven With Low Cash Reserves
…
CERo Therapeutics, Inc. Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236
Company continuing IND-enabling activities in preparation for submission of Investigational New Drug Application to FDA…
Earnings call: Heron Therapeutics reports revenue growth in Q1 2024 By Investing.com
Earnings call: Heron Therapeutics reports revenue growth in Q1 2024…
Heron Therapeutics, Inc. 2024 Q1 - Results - Earnings Call Presentation
…
Heron Therapeutics, Inc. (HRTX) Q1 2024 Earnings Call Transcript
…
Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain
…
Heron Therapeutics, Inc. 2023 Q4 - Results - Earnings Call Presentation
…
Heron Therapeutics, Inc. (HRTX) Q4 2023 Earnings Call Transcript
…